• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Trifluoromethylbenzenes

Introduction to O-{4-chloro-3-(trifluoromethyl)phenylmethyl}hydroxylamine (CAS No. 800379-58-2)

O-{4-chloro-3-(trifluoromethyl)phenylmethyl}hydroxylamine (CAS No. 800379-58-2) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural properties and potential biological activities. This compound is characterized by its hydroxylamine functional group and a substituted phenyl ring, which contribute to its reactivity and biological interactions.

The chemical structure of O-{4-chloro-3-(trifluoromethyl)phenylmethyl}hydroxylamine consists of a hydroxylamine moiety attached to a benzene ring substituted with a chlorine atom at the 4-position and a trifluoromethyl group at the 3-position. The presence of these substituents imparts distinct electronic and steric effects, making this compound an interesting candidate for various applications in drug discovery and development.

Recent studies have explored the potential of O-{4-chloro-3-(trifluoromethyl)phenylmethyl}hydroxylamine as a lead compound for the development of novel therapeutic agents. One notable area of research is its use as an inhibitor of specific enzymes involved in disease pathways. For instance, it has been investigated for its ability to inhibit histone deacetylases (HDACs), which are implicated in various cancers and inflammatory diseases. The hydroxylamine group can form covalent bonds with the active site of HDACs, leading to potent inhibition and potential therapeutic benefits.

In addition to its enzymatic inhibition properties, O-{4-chloro-3-(trifluoromethyl)phenylmethyl}hydroxylamine has also shown promise in modulating other biological targets. Research has demonstrated its ability to interact with G protein-coupled receptors (GPCRs), which are key targets for many drugs used in treating cardiovascular, neurological, and metabolic disorders. The compound's ability to selectively bind to specific GPCRs could lead to the development of more targeted and effective therapies.

The synthesis of O-{4-chloro-3-(trifluoromethyl)phenylmethyl}hydroxylamine involves several well-established chemical reactions, including nucleophilic substitution and reduction steps. These synthetic routes are crucial for producing the compound in sufficient quantities for further research and development. Recent advancements in synthetic chemistry have also focused on optimizing these routes to improve yield, purity, and scalability, making it more feasible for large-scale production.

From a pharmacological perspective, the safety and efficacy of O-{4-chloro-3-(trifluoromethyl)phenylmethyl}hydroxylamine have been evaluated through various preclinical studies. These studies have assessed its toxicity, pharmacokinetics, and biodistribution properties. Results have shown that the compound exhibits favorable pharmacological profiles, with low toxicity and good bioavailability, making it a promising candidate for further clinical investigation.

Clinical trials are an essential step in translating laboratory findings into practical therapeutic applications. While no clinical trials specifically involving O-{4-chloro-3-(trifluoromethyl)phenylmethyl}hydroxylamine have been reported yet, preclinical data suggest that it has the potential to be developed into a novel drug candidate. Ongoing research is focused on identifying optimal dosing regimens, evaluating long-term safety, and exploring combination therapies with other drugs to enhance efficacy.

In conclusion, O-{4-chloro-3-(trifluoromethyl)phenylmethyl}hydroxylamine (CAS No. 800379-58-2) is a versatile compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique structural features and biological activities make it an attractive candidate for developing new therapeutic agents targeting various diseases. Continued research into its properties and applications will likely lead to important advancements in drug discovery and development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)